TUESDAY, june 16  12:00PM ET

A Targeted Approach to CAR T Cell Therapy
Jeffrey F. Eisenberg
Chief Executive Officer

Mr. Eisenberg was appointed Chief Executive Officer of Xenetic in October 2017. He joined Xenetic's management team in December 2016 as Chief Operating Officer and has served on the Company's Board of Directors since July 2016. He is a seasoned life science executive with over 20 years of broad operational expertise. Over the course of his career, Mr. Eisenberg has led all crucial areas of R&D, operations, manufacturing/quality, business development, strategic partnering, product development, commercialization, and talent management. Prior to joining Xenetic, his most recent position was Chief Executive Officer of Noven Pharmaceuticals, where during his tenure as CEO revenues more than doubled, the company's cash increased by more than 300%, and two new products were launched following the successful filings of New Drug Applications (NDAs) submitted to the U.S. Food and Drug Administration. Mr. Eisenberg also was responsible for leading Noven's Novogyne joint venture with Novartis (NYSE: NVS), an entity that generated over $300 million in revenue in its last full year of operation.

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Moderated by:
Jenene Thomas, CEO, JTC Team
© 2020 Virtual Investor  All rights reserved.
Fireside_Masthead3DAYS_Artboard 2.png
Asset 1.png